Yanling Jin

Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial.

Jianqing Xu, Xiaoyan Zhang, Chenli Qiu, 2022, Clinical immunology.

Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.

Jianqing Xu, Xiaoyan Zhang, Jing Wang, 2022, Immunotherapy.

Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Hongzhou Lu, Lin Zhang, S. Yuan, 2020, The Journal of Infectious Diseases.

Early plasma IL-37 responses accompanied with low inflammatory cytokines correlate with benign clinical outcomes during SARS-CoV-2 infection.

Hongzhou Lu, Lin Zhang, S. Yuan, 2020, The Journal of infectious diseases.

CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

Xiaojing Ma, Fang Wei, Qiliang Cai, 2018, Cancer Immunology, Immunotherapy.

Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors

Jianqing Xu, Chen Zhao, Xiaoyan Zhang, 2022, Frontiers in Bioengineering and Biotechnology.

Proteomic profiling identifies the SIM‐associated complex of KSHV‐encoded LANA

Yi Guo, E. Robertson, Fang Wei, 2015, Proteomics.

Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

Jianqing Xu, Xiaoyan Zhang, Wei Zhang, 2023, Cancer research communications.